pharmaceutical investing AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases at 2026 Digestive Disease Week® 05 May
pharmaceutical investing SKYRIZI® Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis 04 May
pharmaceutical investing AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec 30 April
